Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Tsuda, A. Kitamura, N. Nishimura, N. Yagi, S. Takayama, K. Okafuji, Y. Tomishima, T. Jinta, K. Koyama, S. Ohde, K. Gotoh, N. Chohnabayashi (Tokyo, Japan). Safety of pemetrexed according to the duration of vitamin B12 and folic acid supplementation prior to the first dose of pemetrexed. Eur Respir J 2014; 44: Suppl. 58, 2724

Member's Comments

No comment yet.

Related content which might interest you: Maintenance therapy with pemetrexed in non-small-cell lung cancer: Impact on survival Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Safety and efficacy of erlotinib in patients with squamous cell lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Efficiency of erythropoiesis-stimulating agents (ESA) in the treatment of chemotherapy-induced anemia in patients with lung cancer (LC) Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Combination of oral and parenteral vinorelbine with cisplatin or carboplatin in adjuvant chemotherapy of nonsmall cell lung cancer - SWITCH study Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Gefitinib in front line treatment of patients with NSCLC in the Czech Republic: Analysis of 113 patients Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatin/vinorelbine (CVb) - TREAT Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014 TTF 1- expression and pemetrexed based chemotherapy. A retrospective analysis Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Metronomic chemotherapy in human lung cancer: Mathematical modeling for an optimal schedule Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Long-term survival is linked to serum LDH normalization in SCLC Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Chemotherapy beyond 3rd line in NSCLC – A retrospective analysis Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015 Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Effects of high dose vitamin D supplementation in patients undergoing oesophagectomy Source: Annual Congress 2013 –Acute lung injury: novel clinical and experimental insights Year: 2013 Assessment of nutritional status in patients with primary lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Comorbitities, responses and survival in pts with NSCLC Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Effectiveness of oral metronomic Vinorelbine versus Docetaxel as second-line treatment in Non-Small Cell Lung Cancer patients in real life Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Gene therapy with DDMC-p53 with or without cisplatin and microwave ablation. A future concept for local treatment in lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Nutrition and lung cancer Source: International Congress 2016 – Quality management and quality of life in lung cancer Year: 2016 Metabolic signatures associated with lung cancer using serum samples. Influence of hemolysis Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Progression vs. pseudo progression in the treatment of squamous NSCLC with nivolumab Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016